Global Canine Arthritis Treatment Market Growth, Size, Trends Analysis- By Treatment Type, By Arthritis Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Global Canine Arthritis Treatment Market Growth, Size, Trends Analysis- By Treatment Type, By Arthritis Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Apr-2025 | Report ID: PHAR2505 | Pages: 1 - 244 | Formats*: |
| Category : Pharmaceutical | |||
Canine Arthritis Treatment MarketIntroduction and Overview
According to SPER Market Research, the Global Canine Arthritis Treatment Market is estimated to reach USD 4.08 billion by 2034 with a CAGR of 4.95%
The report includes an in-depth analysis of the Global Canine Arthritis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. Arthritis is a common chronic condition in dogs, particularly in aging pets or those with genetic predispositions. Contributing factors like obesity, joint injuries, and breed susceptibility have led to a rise in cases. Increased awareness and early diagnosis by veterinarians and pet owners have also contributed to the growing treatment market. Canine arthritis treatment focuses on pain management, reducing inflammation, improving joint function, and enhancing overall quality of life. Treatment options vary based on the severity, age, breed, size, and health of the dog. The global demand for arthritis treatments is driven by heightened awareness of pet health. However, the high cost of treatment may limit market growth to some extent.
By Treatment Type:
The market for canine arthritis treatments is categorized into drugs, supplements, surgical procedures, and other types, with drugs holding the largest share. Drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids are effective in relieving pain and inflammation while improving joint function in affected dogs. Ongoing research and development are driving the creation of new and improved medications. Pharmaceutical companies are focused on developing innovative drug formulations, delivery methods, and therapeutic targets to enhance the effectiveness and safety of arthritis treatments for dogs.
By Arthritis Type:
The canine arthritis treatment market is divided into osteoarthritis, osteochondrosis, rheumatoid arthritis, and traumatic arthritis, with osteoarthritis being the most common. Osteoarthritis is particularly prevalent in older dogs, and the aging pet population is contributing to the overall rise in cases. A significant factor in the increasing incidence of osteoarthritis in dogs is the rise in pet obesity. Extra body weight puts additional stress on the joints, leading to faster wear and tear, which increases the likelihood of developing osteoarthritis.
By Regional Insights
The North American canine arthritis treatment market is expected to grow steadily due to the increasing adoption of companion animals, a rising prevalence of canine arthritis, and higher spending on pet healthcare. The growing number of pet dog owners and increased awareness about proper pet health are key drivers of market expansion. As more households keep dogs as pets, the demand for effective arthritis treatments and greater focus on animal well-being will further fuel the growth of the market in the region.
Market Competitive Landscape
The market is moderately consolidated. Some of the market key players are American Regent, Inc., Bayer AG, Boehringer Ingelheim Animal Health, CEVA Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, Nutramax Laboratories Veterinary Sciences, Inc., Vetoquinol SA, VetStem, Inc., and Virbac, along with other players in the industry.
Recent Developments:
In May 2023, Zoetis received approval from the U.S. Food and Drug Administration (FDA) for Librela (bedinvetmab injection) to treat osteoarthritis (OA) pain in dogs. Librela is a monthly anti-nerve growth factor (NGF) monoclonal antibody treatment designed to reduce pain associated with canine OA. This approval represents a major breakthrough in pain management for dogs, providing a safe and effective long-term solution that improves their mobility and strengthens Zoetis' product portfolio.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Treatment Type, By Arthritis Type |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | American Regent, Inc., Bayer AG, Boehringer Ingelheim Animal Health, CEVA Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, Nutramax Laboratories Veterinary Sciences, Inc., Vetoquinol SA, VetStem, Inc., and Virbac, along with other players in the industry. |
Key Topics Covered in the Report
- Global Canine Arthritis Treatment Market Size (FY’2021-FY’2034)
- Overview of Global Canine Arthritis Treatment Market
- Segmentation of Global Canine Arthritis Treatment Market By Treatment Type (Drugs, Supplements, Surgical Procedures, Others)
- Segmentation of Global Canine Arthritis Treatment Market By Arthritis Type (Osteoarthritis, Osteochondrosis, Rheumatoid arthritis, Traumatic arthritis.)
- Statistical Snap of Global Canine Arthritis Treatment Market
- Expansion Analysis of Global Canine Arthritis Treatment Market
- Problems and Obstacles in Global Canine Arthritis Treatment Market
- Competitive Landscape in the Global Canine Arthritis Treatment Market
- Details on Current Investment in Global Canine Arthritis Treatment Market
- Competitive Analysis of Global Canine Arthritis Treatment Market
- Prominent Players in the Global Canine Arthritis Treatment Market
- SWOT Analysis of Global Canine Arthritis Treatment Market
- Global Canine Arthritis Treatment Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analys
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Canine Arthritis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Canine Arthritis Treatment Market
7. Global Canine Arthritis Treatment Market, By Treatment Type, (USD Million) 2021-2034
7.1. Drugs
7.1.1. Non-steroidal anti-inflammatory drugs (NSAID’s)
7.1.2. Corticosteroids
7.1.3. Opioid pain relievers
7.1.4. Other drugs
7.2. Supplements
7.2.1. Glucosamine
7.2.2. Chondroitin
7.2.3. Methylsulfonylmethane
7.2.4. Other supplements
7.3. Surgical procedures
7.4. Other treatment types
8. Global Canine Arthritis Treatment Market, By Arthritis Type, (USD Million) 2021-2034
8.1. Osteoarthritis
8.2. Osteochondrosis
8.3. Rheumatoid arthritis
8.4. Traumatic arthritis
9. Global Canine Arthritis Treatment Market, (USD Million) 2021-2034
9.1. Global Canine Arthritis Treatment Market Size and Market Share
10. Global Canine Arthritis Treatment Market, By Region, 2021-2034 (USD Million)
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. American Regent, Inc.
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Bayer AG
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Boehringer Ingelheim Animal Health
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. CEVA Santé Animale
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Dechra Pharmaceuticals PLC
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Elanco Animal Health
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Nutramax Laboratories Veterinary Sciences, Inc.
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Vetoquinol SA
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. VetStem, Inc.
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Virbac
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Canine Arthritis Treatment Market is projected to reach USD 4.08 billion by 2034, growing at a CAGR of 4.95% during the forecast period.
Canine Arthritis Treatment Market size from 2025. The Market is expected to reach USD 4.08 billion by 2034, at a CAGR of 4.95% during the forecast period.
Canine Arthritis Treatment Market CAGR of4.95% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Canine Arthritis Treatment Marketsize is 4.08 billion from 2025 to 2034.
" Canine Arthritis Treatment Market is covered By Treatment Type, By Arthritis Type
"
The North America is anticipated to have the highest Market share in the Canine Arthritis Treatment Market .
"American Regent, Inc., Bayer AG, Boehringer Ingelheim Animal Health, CEVA Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, Nutramax Laboratories Veterinary Sciences, Inc., Vetoquinol SA, VetStem, Inc., and Virbac, along with other players in the industry.
"
The report includes an in-depth analysis of the Global Canine Arthritis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
